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Hepcidin produced in the liver negatively regulates intestinal iron absorption, and the 
bone morphogenetic protein (BMP) pathway is well-known to stimulate hepcidin 
expression. However, the regulation of hepcidin expression has not been fully 
elucidated. In this study, we evaluate different systems that can be used to determine 
how hepcidin expression is regulated. The basal expression of hepcidin in liver cell lines, 
such as HepG2 cells and Hepa1-6 cells, was lower than that in the liver and primary 
hepatocytes; the expression levels of hepcidin in the cell lines were near the limit of 
detection for RT-PCR and RT-qPCR analyses. Treatment with trichostatin A, RNAlater, 
or MG-132 enhanced the expression of hepcidin in HepG2 cells, suggesting that histone 
deacetylation, instability of mRNA, or proteosomal degradation of the protein(s) that 
positively regulate hepcidin expression may be responsible for the decreased expression 
of hepcidin in HepG2 cells. In luciferase-based reporter assays, BMP induced the 
transcription of a reporter, hepcidin(-2018)-luc, that contains nt -2018 through nt -35 of 
the hepcidin promoter in HepG2 cells and Hepa1-6 cells. However, BRE-luc, a 
representative reporter used to evaluate BMP signaling, was unresponsive to BMP in 
HepG2 cells. These results suggest that hepcidin transcription can be best evaluated in 
liver cell lines and that the hepcidin promoter senses BMP signaling with high 
sensitivity. The present study demonstrates that studies regarding the regulation of 
hepcidin expression at the mRNA level should be evaluated in primary hepatocytes, and 






BMP, bone morphogenetic proteins; CMF, calcium and magnesium-free; HBSS, Hank’s 
buffered salt solution; DMEM, Dulbecco’s modified Eagle’s medium, FBS, fetal bovine 
serum; ALK, activin receptor-like kinase; RT-PCR, reverse transcription-polymerase 
chain reaction; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; 
Gapdh, glyceraldehyde-3-phosphate dehydrogenase ; pCMV-Gal, plasmid expressing 
-galactosidase under the control cytomegalovirus promoter; SEM, standard error of the 
mean; Id1, inhibitor of differentiation 1; Hprt1, hypoxanthine phosphoribosyltransferase 
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The iron uptake of the body is tightly regulated through the modulation of its absorption 
from the intestine (Lee and Beutler, 2009). Ferric iron is reduced at the luminal site by 
intestinal cytochrome b, and ferrous iron is transferred into the enterocyte via the 
transmembrane protein divalent metal transporter-1. On the basolateral side, ferrous iron 
is exported from enterocytes to the circulatory system via ferroportin, and after being 
oxidized by the membrane bound ferroxidase hephaestin, iron is incorporated into 
transferrin (Ganz and Nemeth, 2012). 
 
Hepcidin is a 25-amino acid antimicrobial peptide that serves as the central regulator of 
intestinal iron absorption (Lee and Beutler, 2009). Hepcidin binds to the iron exporter 
ferroportin and induces its endocytosis and proteolysis, thus preventing intestinal 
absorption of iron (Nemeth et al., 2004; De Domenico et al., 2007). Previous studies 
suggested that hepcidin activity is mainly regulated at the gene transcript level (Ganz 
and Nemeth, 2012). The ratio of intestinal iron absorption to iron intake decreases as 
dietary iron levels increase (Laftah et al., 2004), and this is achieved by the 
up-regulation of hepatic hepcidin expression (Kautz et al., 2008; Corradini et al., 2009). 
The current model suggests that hepcidin expression is transcriptionally regulated by the 
pathway induced by bone morphogenetic proteins (BMPs) such as BMP2, BMP4, 
BMP6 and BMP9 (Babitt et al., 2006, Truksa et al., 2006; Babbit et al., 2007; 
Muckenthaler, 2008; Lee and Beutler, 2009). Increased levels of iron have been shown 
to increase the hepatic expression of BMP6 (Kautz et al., 2008), and the disruption of 
BMP6 resulted in decreased hepatic hepcidin expression and the accumulation of iron in 
the liver (Andriopoulos et al., 2009; Meynard et al., 2009). However, factors other than 
the BMPs are also involved in modulating hepcidin expression (Muckenthaler, 2008; 
Lee and Beutler, 2009; Goodnough et al. 2012), indicating that the mechanisms 




While exploring the factors that affect hepcidin expression, we noticed that hepcidin 
expression in liver cell lines is extremely low compared to that in the liver and primary 
hepatocytes, and this low level of expression makes it difficult to evaluate the regulation 
of hepcidin at the mRNA level. The main objective of this study is to clarify the 
differences of the hepcidin expression level among the livers, primary hepatocytes and 
liver cell lines. The present study provides information on cultured cell systems suitable 
for evaluating hepcidin expression. 
 
 
2. Materials & methods 
2.1. Animals and cell culture 
Animal experiments were approved by the Kyoto University Animal Experiment 
Committee or the Azabu University Animal Experiment Committee. Mouse and rat 
livers were obtained from normal adult C57BL/6 mice and Sprague-Dawley rats, 
respectively. Primary rat hepatocytes were isolated by collagenase digestion of livers 
from male Wistar rats weighing 200 to 300 g. Livers were perfused from the portal vein 
to the incised inferior vena cava with calcium and magnesium-free (CMF) buffer 
consisting of 40 mM Hepes, pH 7.4, 120 mM NaCl, 5.4 mM KCl, 5.0 mM NaHCO3 and 
5.6 mM glucose supplemented with 100 U/mL penicillin, 100 g/mL streptomycin and 
250 ng/mL amphotericin B for 10 min at a rate of ~12 mL/min followed by perfusion 
with CMF buffer containing 0.05% collagenase (Wako, Tokyo, Japan) for 10 min. 
Subsequently, hepatocytes were liberated into Hank’s buffered salt solution (HBSS), i.e., 
140 mM NaCl, 5.4 mM KCl, 0.34 mM Na2HPO4, 0.44 mM KH2PO4, 0.81 mM 
MgSO4∙7H2O, 1.3 mM CaCl2, 4.2 mM NaHCO3 and 5.6 mM glucose supplemented 
with 100 U/mL penicillin, 100 g/mL streptomycin and 250 ng/mL amphotericin B. 
After cell recovery by centrifugation at 50 × g for 2 min, the cells were washed with 
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HBSS three times and resuspended in Dulbecco’s modified Eagle’s medium (DMEM) 
with 10% fetal bovine serum (FBS) and antibiotics. Cells (>90% hepatocytes by 
microscopy) were seeded on collagen-coated plates at 1.5 ×105 cells per well in 
12-well plates. After attachment, the medium was replaced with the same medium, and 
the cells were incubated for 24 h. Then, cells were treated with or without BMP2 (4 nM; 
R & D Systems, Minneapolis, MN, USA) in the presence or absence of cycloheximide 
(0.5 g/mL) for 12 h.  
 
HepG2 hepatoma cells, Hepa1-6 hepatoma cells and 3T3-L1 preadipocytes were 
cultured in DMEM with 10% FBS and antibiotics. For the luciferase-based reporter 
assays, these cells were transiently transfected using PolyFect transfection reagent 
(Qiagen, Valencia, CA, USA) or polyethylenimine Max reagent (Polysciences, 
Warrington, PA, USA), according to the manufacturers' protocols. At 24 h 
post-transfection, the cells were pre-treated with or without LDN-193189 (100 nM), an 
inhibitor of the BMP type I receptor (Cuny et al., 2008), for 15 min before BMP2 (4 
nM) treatment for 16 h. To evaluate the expression of constitutively active activin 
receptor-like kinase (ALK) 3 (ALK3(QD)), cells were harvested at 36 h 
post-transfection. To evaluate the levels of hepcidin mRNA, HepG2 cells and Hepa1-6 
cells were treated for 24 h with or without trichostatin A (TSA: 0.1 g/mL; Wako, 
Tokyo, Japan), an inhibitor of class I and II histone deacetylases (Gräff and Tsai, 2013), 
RNAlater (0.1 or 1%; Life Technologies, Carlsbad, CA, USA) to denature RNase at a 
controlled pH (Zaitoun et al., 2010) or MG-132 (20 M; EMD Millipore, Billerica, MA, 
USA), a proteasome inhibitor (Tsubuki et al., 1993). In Hepa1-6 cells, treatment with 
MG-132 at 20 M caused detachment of the cells from culture dish, and, therefore, we 
also treated with MG-132 at 10 M. 
 
2.2. RNA isolation, RT-PCR and RT-quantitative PCR 
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Total RNA was isolated from livers and cells, and cDNA was synthesized using 
TRIZOL (Invitrogen, Grand Island, NY, USA) and ReverTra Ace qPCR RT kit (Toyobo, 
Osaka, Japan), respectively, according to the manufacturers’ protocols. The cDNA 
reverse-transcribed from 5 or 20 ng of total RNA was used as a template for 
conventional reverse transcription-polymerase chain reaction (RT-PCR) or RT- 
quantitative PCR (RT-qPCR) using SYBR Green I (Thunderbird SYBR qPCR mix, 
Toyobo, Osaka, Japan) as described previously (Asano et al., 2013). The 
oligonucleotide primers for the conventional RT-PCR and RT-qPCR are presented in 
Table 1. The Ct value was determined, and the abundance of gene transcripts was 
analyzed using the ▵▵Ct method using glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh) as the normalization gene (Duran et al., 2005). 
 
2.3. Plasmids and reporter assays 
Plasmids were obtained as follows: BRE-luc reporter plasmids (Korchynskyi and ten 
Dijke, 2002) was from Dr. P. ten Dijke, and ALK3(QD) (Imamura et al., 1997) was 
obtained from Dr. K. Miyazono. The DNA fragment spanning from -2018 bp to -35 bp 
of the mouse hepcidin (Hamp1) promoter was amplified and cloned into the basic 
vector pGL4 containing the firefly luciferase reporter (Hepcidin (-2018)-luc) with nt +1 
as the translation initiation site. The product was verified through nucleotide sequencing. 
Luciferase-based reporter assays were conducted as described previously (Murakami et 
al., 2009). Cells were transiently transfected with the indicated expression vectors, 
reporter construct and a plasmid expressing -galactosidase under the control 
cytomegalovirus promoter (pCMV-Gal). Equal amounts of DNA were transfected in 
each experiment and adjusted with empty vector. Luciferase activity was normalized to 
the -galactosidase activity, and the luciferase activity in the cell lysate transfected 




2.4. Statistical analyses 
Data are expressed as the mean  standard error of the mean (SEM). Data on gene 
expression were log-transformed to provide an approximation of a normal distribution 
before analysis. Differences between control cells and BMP2-treated cells, between 
cycloheximide-treated and untreated cells, and between LDN-193189-treated and 




3. Results and discussion 
3.1. Hepcidin expression is lower in cell lines than in liver and primary 
hepatocytes 
Hepcidin expression was examined in mouse and rat livers, rat primary hepatocytes and 
the human HepG2 and mouse Hepa1-6 liver cell lines. To compare the hepcidin 
expression levels, we designed PCR primers to amplify both mouse hepcidin (Hamp1) 
and rat hepcidin (Fig. 1A), and both human hepcidin and mouse hepcidin (Fig. 1B). 
Significant hepcidin expression was detected in livers and primary hepatocytes, but the 
levels of hepcidin expression in HepG2 cells and Hepa1-6 cells was lower or below the 
limit of detection. Gapdh and hypoxanthine phosphoribosyltransferase 1 (Hprt1), 
house-keeping genes, were individually amplified by use of common PCR primers 
applicable to human, mouse and rat Gapdh and Hprt1. The Gapdh levels tended to be 
higher in HepG2 cells and Hepa1-6 cells than in the livers and primary hepatocytes, and 
the Hprt1 levels were higher in primary hepatocytes and liver cell lines (Fig. 1C). 
 
We also examined hepcidin expression by RT-qPCR analyses (Fig. 2). Consistent with 
the RT-PCR analyses (Fig. 1), hepcidin expression level in primary hepatocytes was as 
high as that in the livers (Fig. 2A), whereas hepcidin expression level was below 
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detection limit in the liver cell lines, including HepG2 cells and Hepa1-6 cells (Fig. 2B). 
In some samples, we could detect significant fluorescence in qPCR more than 35 cycles 
in HepG2 cells, but it was not reproducible (data not shown). Hepcidin mRNA level has 
been clearly detected in liver cell lines including HepG2 cells (Ravasi et al., 2012); the 
discrepancy could be due to the differences of the sensitivity of RT-qPCR analyses. The 
RT-qPCR analyses for Gapdh and Hprt1 indicated clear expression in all samples (Fig. 
2C and D); similar to the RT-PCR analyses (Fig. 1), expression level in the liver 
samples tended to be lower than that in the primary hepatocytes and liver cell lines. All 
these results suggest that hepcidin expression levels in liver cell lines are lower than 
those in the livers and primary hepatocytes, and that the lower expression of hepcidin in 
the liver cell lines is not due to a non-specific decrease in gene transcript levels. 
 
There are several possible explanations for the lower hepcidin mRNA levels in the liver 
cell lines. Hepcidin mRNA is negatively regulated by Tmprss6, a transmembrane 
matriptase-2 (Du et al., 2008); the increase in Tmprss6 mRNA levels in response to 
BMP treatment is delayed compared to the up-regulation of hepcidin expression, 
indicating a negative feedback loop to avoid excess hepcidin expression (Meynard et al., 
2011). Because the lower expression of hepcidin in the liver cell lines likely results from 
higher expression of Tmprss6, we examined the Tmprss6 expression level in liver cell 
lines. However, Tmprss6 expression was undetectable in the liver cell lines (Fig. 1D). 
Thus, the low level of hepcidin expression in the liver cell lines is not due to high levels 
of Tmprss6. 
 
We also examined the potential roles of histone deacetylase activation and mRNA 
instability in the low expression of hepcidin in liver cell lines. Treatment with TSA 
robustly increased the expression of hepcidin in HepG2 cells but not in Hepa1-6 cells, 
although the expression level in cells without TSA treatment was near the limit of 
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detection (Fig. 3A). Hepcidin expression was also induced by treatment with an RNase 
inhibitor in HepG2 cells but not in Hepa1-6 cells (Fig. 3B). Unlike Hepa1-6 cells, 
transcriptional repression due to histone deacetylation, mRNA instability or both may 
be responsible for the low levels of hepcidin in HepG2 cells. We further examined the 
effect of MG-132 on hepcidin expression. Treatment with MG-132 increased hepcidin 
transcription in HepG2 cells but not in Hepa1-6 cells (Fig. 3C). These results suggest 
the different reason underlying the lower expression level of hepcidin between HepG2 
cells and Hepa1-6 cells. Future studies are needed to clarify the reason of the lower 
expression of hepcidin in Hepa1-6 cells. Additionally, histone acetylation within the 
hepcidin promoter and hepcidin mRNA instability should be also evaluated to clarify 
the relation to the silencing of hepcidin in HepG2 cells. Furthermore, the molecule(s) 
that positively regulate hepcidin, which is degraded by proteasome, should be identified 
in HepG2 cells. 
 
As described above, the activation of hepcidin expression by the BMP pathway is well 
known (Babitt et al., 2006, 2007; Muckenthaler, 2008; Lee and Beutler, 2009). We also 
evaluated hepcidin expression in response to BMP treatment and the effect of 
cycloheximine, a protein synthesis inhibitor, in rat primary hepatocytes. BMP increased 
hepcidin expression 4.5-fold, and cycloheximide partially blocked the up-regulation of 
hepcidin expression (Fig. 4). The results indicate that BMP-induced hepcidin expression 
is partially a direct event, and that it is also enhanced through de novo protein synthesis; 
the results clearly disagree with a previous study using HepG2 cells in which 
cycloheximide did not affect BMP-induced hepcidin expression (Babitt et al., 2006). 
The contradicting conclusions are possibly due to the different cell types used in the 
studies. 
 
The BMP-regulated expression of hepcidin has been studied in various systems, 
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including the liver cell lines such as HepG2, Hep3B and Huh7 cells (Babitt et al., 2006, 
2007; Truksa et al., 2007, 2009; Mleczko-Sanecka et al., 2010). The Lin group has 
examined hepcidin mRNA by RT-qPCR analyses, and their studies revealed that 
treatment with BMP increased the expression of hepcidin by 50 to 1100-fold and 12 to 
25-fold in Hep3B cells and HepG2 cells, respectively. An approximately 8-fold 
induction was detected in mouse and rat primary hepatocytes, and intraperitoneal 
injection of BMP resulted in only a 1.3 to 2-fold increase in hepatic hepcidin expression 
(Babitt et al., 2006, 2007; Andriopoulos et al., 2009; Corradini et al., 2009, 2010; Theurl 
et al., 2011). One explanation for the larger effect BMP treatment on hepcidin 
expression in the liver cell lines may be related to a lower basal expression level; the 
magnitude of the increase in the hepcidin mRNA copy number in response to BMP 
treatment relative to the total hepcidin mRNA is larger when the basal expression is 
lower. Examining hepcidin mRNA in liver cell lines can allow one to overlook factor(s) 
that positively and negatively affect hepcidin expression. 
 
3.2. Hepcidin transcription can be examined in cell lines 
Primary hepatocytes are suitable for examining hepcidin mRNA levels, but they are 
inappropriate for studying the transcriptional regulation of hepcidin using a reporter 
gene; it is generally difficult to transfect primary cells with plasmid DNA, although 
plasmid DNA can be highly transfected in primary cells by use of a special apparatus 
(Gresch and Altrogge, 2012). In contrast, cell lines can be easily transfected with 
plasmid DNA, and the transcriptional regulation of hepcidin has been examined by 
luciferase-based reporter assays in many studies (Truksa et al., 2009; Mleczko-Sanecka 
et al., 2010; Goodnough et al., 2012; Pandur et al., 2013). Consistent with the results of 
previous studies, the expression of hepcidin(-2018)-luc was significantly increased by 
BMP treatment in HepG2 cells (P < 0.01) and was inhibited by pretreatment with 
LDN-193189; both basal expression of the luciferase and the induced expression in 
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response to BMP treatment were significantly decreased (P < 0.01, Fig. 5A). Similar 
results were obtained in Hepa1-6 cells (Fig. 5B). Furthermore, the enhanced 
transcription of hepcidin(-2018)-luc was significantly elicited by the forced expression 
of ALK3(QD), a constitutively active BMP type I receptor (Imamura et al., 1997) (P < 
0.01, Fig. 5C). These results confirm previous results that showed that BMP-induced 
hepcidin transcription is evaluated in liver cell lines. 
 
BRE-luc, which is derived from the promoter region of inhibitor of differentiation 1 
(Id1), a BMP target gene, is a representative reporter that transmits canonical BMP 
signaling (Korchyniskyi and ten Dijke, 2002). Provided that hepcidin transcription is 
stimulated by the BMP pathway in liver cells (Fig. 5A-C), we expected that not only 
hepcidin(-2018)-luc but also BRE-luc is transcriptionally stimulated by the BMP 
pathway. However, the BMP-induced transcriptional activation of BRE-luc was not 
detected in HepG2 cells. 3T3-L1 cells and C2C12 cells are non-liver cells that can 
transmit canonical BMP signaling (Korchyniskyi and ten Dijke, 2002; Rebbapragada et 
al., 2003); in these cells, BMP treatment increased expression of BRE-luc and 
hepcidin(-2018)-luc (P < 0.01, Fig. 5D, data not shown). The higher response of 
hepcidin(-2018)-luc than BRE-luc was also detected when the BMP signal was 
transmitted by ALK3(QD) expression, although ALK3(QD) expression significantly 
increased expression of hepcidin(-2018)-luc (P < 0.01, Fig. 5E). The results suggest that 
it is difficult to evaluate BMP signaling by BRE-luc and that the hepcidin promoter 
senses exogenous BMP with high sensitivity in liver cell lines, thus extending the 
current understanding of how hepcidin expression is regulated by the BMP pathway. 
 
4. Conclusions 
The present study revealed that 1) compared with expression in livers and primary 
hepatocytes, hepcidin expression levels are lower in liver cell lines, 2) the activation of 
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histone deacetylase and the accelerated degradation of mRNA or protein(s) may be 
involved in the lower expression levels of hepcidin in HepG2 cells, and 3) the 
transcriptional regulation of hepcidin, which is highly responsive to BMP, can be 
evaluated in liver cell lines. We conclude that primary hepatocytes should be used to 
examine the regulation of hepcidin expression at the mRNA level. In addition, liver cell 
lines such as HepG2 cells and Hepa1-6 cells should be limited to studies that aim to 
evaluate the transcriptional regulation of hepcidin. 
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Fig. 1. Hepcidin expression in the liver, primary hepatocytes and liver cell lines 
The cDNA was prepared from total RNA from mouse and rat livers, rat primary 
hepatocytes and the liver cell lines HepG2 and Hepa1-6. RT-PCR was performed using 
primers to detect (A) mouse and rat hepcidin using mrHepcidin primer set, (B) human 
and mouse hepcidin using mhHepcidin primer set, (C) human, mouse and rat Gapdh and 
Hprt1 and (D) human, mouse and rat Tmprss6. The PCR products were electrophoresed 
on 2% agarose gels and stained with ethidium bromide. A representative result is shown. 
 
Fig. 2. Lower hepcidin expression in liver cell lines than in the liver and primary 
hepatocytes 
The cDNA was prepared from total RNA from mouse and rat livers, rat primary 
hepatocytes and the liver cell lines HepG2 and Hepa1-6. RT-qPCR was performed using 
primers to detect (A) mouse and rat hepcidin using mrHepcidin primer set, (B) human 
and mouse hepcidin using mhHepcidin primer set, (C) human, mouse and rat Gapdh and 
(D) human, mouse and rat Hprt1. The amplification plots are shown. Note that cDNA 
from HepG2 cells and Hepa1-6 cells was not amplified (B). 
 
Fig. 3. Altered expression of hepcidin by histone deacetylases, RNase and the 
proteasome in HepG2 cells but not in Hepa1-6 cells 
HepG2 cells were treated with TSA (A), RNase inhibitor (B) or MG-132 (C) as 
described in the Materials and Methods. The treatments were performed in 
quadruplicate. The hepcidin (upper) and Gapdh (lower) expression levels were 
examined by RT-PCR. The PCR products were electrophoresed on 2% agarose gels and 
stained with ethidium bromide. A representative result is shown. 
 
Fig. 4. Hepcidin expression and transcription in response to BMP2 in liver cells 
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Rat primary hepatocytes were treated with or without BMP2 in the presence (+) or 
absence (-) of cycloheximide (CHX). Hepcidin expression examined by RT-qPCR using 
rHepcidin primer set was normalized to Gapdh expression, which was quantified by use 
of rGapdh primer set. The expression level in cells treated without BMP2 or 
cycloheximide was set at 1. **: P < 0.01 vs. cells treated without BMP2. ‡: P < 0.01 vs. 
cells treated with BMP2 and without cycloheximide. 
 
Fig. 5. Hepcidin expression and transcription in response to BMP2 in liver cells 
HepG2 cells (A) and Hepa1-6 cells (B) were transiently transfected with 
Hepcidin(-2018)-luc and pCMV-Gal and treated with or without BMP2 in the presence 
(+) or absence (-) of LDN-193189. (C) Hepcidin(-2018)-luc, ALK3(QD) and 
pCMV-Gal were transfected into the indicated cells. (D) The indicated reporter gene 
and pCMV-Gal were transfected in HepG2 and 3T3-L1 cells, and the cells were 
treated with or without BMP2. (E) HepG2 cells were transfected with the indicated 
reporter, ALK3(QD) and pCMV-Gal. Luciferase activity was normalized to 
-galactosidase activity, and luciferase activity in the cell lysates in the absence of 
BMP2, ALK3(QD) and LDN-193189 was set at 1. Data are expressed as the mean  S.E. 





Table 1. Oligonucleotide PCR primers for RT-PCR and RT-qPCR 
 Oligonucleotide GenBank 
 5’-primer 3’-primer accession number 
RT-PCR and qPCR: 
 Gapdh 5’- TTCATTGACCTCAACTACATGGT -3’ 5’- GCTAAGCAGTTGGTGGTGCAGGA -3’ NM_002046 (human) 
     NM_008084 (mouse) 
     NM_017008 (rat) 
  Hprt1
 
5’- ATGGGAGGCCATCACATTG -3’ 5’- CTTTCCAGTTAAAGTTGAGAGATCA -3’ NM_000194 (human) 
     NM_013556 (mouse) 
     NM_012583 (rat) 
 mhHepcidin
1
 5’- TGCCTCCTGCTCCTCCTCCT -3’ 5’- GCAGAAAATGCAGATGGGGAAGT -3’ NM_021175 (human) 
     NM_032541 (mouse) 
 mrHepcidin
2
 5’- GCTGCCTGTCTCCTGCTT -3’ 5’- TTACAGCATTTACAGCAGAAGAGG -3’ NM_053469 (rat) 
     NM_032541 (mouse) 
 
RT-PCR:  
 Tmprss6 5’- CACTGTGACTGTGGCCTCCAGG -3’ 5’- CGTCGTAGTCATGGCTGTCCTC -3’ NM_153609 (human) 
     NM_027902 (mouse) 
     NM_001130556 (rat) 
 
RT-qPCR: 
 rGapdh 5’- ACAACTTTGGCATCGTGGA -3’ 5’- CTTCTGAGTGGCAGTGATGG -3’ NM_017008 (rat) 
 rHepcidin 5’- GCTGCCTGTCTCCTGCTT -3’ 5’- AGCCGTAGTCTGTCTCGTCT -3’ NM_053469 (rat) 
1
PCR primers common to mouse and human hepcidin. 
2
PCR primers common to mouse and rat hepcidin. 
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